CL2016002569A1 - Anticuerpos, composiciones farmacéuticas y usos de los mismos - Google Patents

Anticuerpos, composiciones farmacéuticas y usos de los mismos

Info

Publication number
CL2016002569A1
CL2016002569A1 CL2016002569A CL2016002569A CL2016002569A1 CL 2016002569 A1 CL2016002569 A1 CL 2016002569A1 CL 2016002569 A CL2016002569 A CL 2016002569A CL 2016002569 A CL2016002569 A CL 2016002569A CL 2016002569 A1 CL2016002569 A1 CL 2016002569A1
Authority
CL
Chile
Prior art keywords
antibodies
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
CL2016002569A
Other languages
English (en)
Spanish (es)
Inventor
Cheng-Chi Wang
Cheng-Der Tony Yu
I-Ju Chen
Jiann-Shiun Lai
Yi-Chien Tsai
Original Assignee
Obi Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc
Publication of CL2016002569A1 publication Critical patent/CL2016002569A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
CL2016002569A 2014-04-10 2016-10-07 Anticuerpos, composiciones farmacéuticas y usos de los mismos CL2016002569A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977824P 2014-04-10 2014-04-10
US201462057381P 2014-09-30 2014-09-30

Publications (1)

Publication Number Publication Date
CL2016002569A1 true CL2016002569A1 (es) 2017-09-08

Family

ID=54288553

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002569A CL2016002569A1 (es) 2014-04-10 2016-10-07 Anticuerpos, composiciones farmacéuticas y usos de los mismos

Country Status (17)

Country Link
US (2) US9902779B2 (en:Method)
EP (2) EP3129048B1 (en:Method)
JP (1) JP2017512759A (en:Method)
KR (1) KR101966408B1 (en:Method)
CN (2) CN106456727B (en:Method)
AU (2) AU2015243246B2 (en:Method)
BR (1) BR112016020009A2 (en:Method)
CA (2) CA2941029C (en:Method)
CL (1) CL2016002569A1 (en:Method)
ES (1) ES2772817T3 (en:Method)
IL (2) IL246837B (en:Method)
PH (1) PH12016501976A1 (en:Method)
RU (1) RU2016138744A (en:Method)
SG (1) SG11201607258SA (en:Method)
TW (3) TWI695013B (en:Method)
WO (1) WO2015157629A2 (en:Method)
ZA (1) ZA201605175B (en:Method)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2924286C (en) 2013-09-17 2022-06-21 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US20170143810A1 (en) 2014-03-19 2017-05-25 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
JP2017512759A (ja) 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
KR20180050339A (ko) 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
US10501532B2 (en) 2015-10-07 2019-12-10 Obi Pharma, Inc. Carbohydrate antibodies, pharmaceutical compositions and uses thereof
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
MY200886A (en) 2016-04-22 2024-01-22 Obi Pharma Inc Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
TWI752988B (zh) 2016-07-27 2022-01-21 台灣浩鼎生技股份有限公司 免疫性/治療性聚醣組合物及其用途
JP7121724B2 (ja) 2016-07-29 2022-08-18 オービーアイ ファーマ，インコーポレイテッド ヒト抗体、医薬組成物及び方法
KR20190077103A (ko) * 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 접합된 생물학적 분자, 제약 조성물 및 방법
WO2018218068A1 (en) * 2017-05-24 2018-11-29 Development Center For Biotechnology Humanized antibodies against globo h and uses thereof in cancer treatments
KR20200131846A (ko) 2018-03-14 2020-11-24 메모리얼 슬로안 케터링 캔서 센터 항-폴리시알산 항체 및 그 용도
EP3801607A4 (en) * 2018-06-01 2022-03-16 OBI Pharma, Inc. Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody
TWI853822B (zh) 2018-06-27 2024-09-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US20250327822A1 (en) * 2019-03-28 2025-10-23 Ming-Tain Lai Companion diagnostic assay for globo-h related cancer therapy
AU2022219922A1 (en) * 2021-02-09 2023-06-22 Obi Pharma, Inc. Globo series antigens-binding chimeric antigen receptors and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
JP5084984B2 (ja) 1999-02-17 2012-11-28 シーエスエル、リミテッド 免疫原複合体およびそれに関する方法
AU6015301A (en) 2000-03-24 2001-10-03 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
ES2276735T3 (es) * 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
BR0107262B1 (pt) 2001-12-17 2014-04-22 Da Fonseca Clovis Orlando Pereira Composição farmacêutica inalatória
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
US7438911B2 (en) * 2002-04-30 2008-10-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
AT413486B (de) * 2002-07-03 2006-03-15 Igeneon Krebs Immuntherapie Verwendung eines antikörpers gerichtet gegen lewis-antigene
NZ580828A (en) 2004-02-06 2011-09-30 Univ Massachusetts Antibodies against clostridium difficile toxin B and uses thereof
AU2005259221B2 (en) * 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
CN101128483B (zh) * 2004-12-21 2015-06-03 阿斯利康公司 血管生成素-2的抗体及其应用
LT1871805T (lt) * 2005-02-07 2019-12-10 Roche Glycart Ag Antigeną surišančios molekulės, kurios suriša egfr, jas koduojantys vektoriai ir jų panaudojimas
JP5238936B2 (ja) * 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008087259A1 (en) * 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
KR101324109B1 (ko) 2008-06-16 2013-10-31 아카데미아 시니카 Ｇｌｏｂｏ ｈ 및 그의 절편들에 대한 항체의 양에 따른 암 진단방법
EP2303286A4 (en) 2008-06-16 2011-12-28 Academia Sinica COMPOSITIONS FOR GENERATING IMMUNE REACTIONS SPECIFIC TO GLOBO H AND SSEA3 AND THEIR USES IN CANCER TREATMENT
TWI583393B (zh) * 2009-06-16 2017-05-21 中央研究院 免疫原性組合物、包含其之疫苗與治療劑及其用途
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CA2795799C (en) * 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anti-erbb3 antibodies
EA201300074A1 (ru) * 2010-07-01 2013-06-28 ДСМ АйПи АССЕТС Б.В. Способ получения представляющего интерес соединения
MA34520B1 (fr) * 2010-08-16 2013-09-02 Amgen Inc Anticorps se liant à la myostatine, compositions et procédés
WO2012088094A2 (en) * 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP2497782A1 (en) * 2011-03-08 2012-09-12 Alzinova AB Anti oligomer antibodies and uses thereof
CN108753942A (zh) 2011-10-06 2018-11-06 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
RS56443B1 (sr) 2012-02-24 2018-01-31 Abbvie Stemcentrx Llc Ddl3 modulatori i postupci primene
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US20170143810A1 (en) * 2014-03-19 2017-05-25 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
JP2017512759A (ja) 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途

Also Published As

Publication number Publication date
EP3662928A1 (en) 2020-06-10
SG11201607258SA (en) 2016-10-28
WO2015157629A2 (en) 2015-10-15
IL276695B (en) 2021-09-30
ZA201605175B (en) 2017-09-27
JP2017512759A (ja) 2017-05-25
TW201546092A (zh) 2015-12-16
EP3129048A4 (en) 2017-10-25
US9902779B2 (en) 2018-02-27
WO2015157629A3 (en) 2015-12-03
KR20160137984A (ko) 2016-12-02
IL246837A0 (en) 2016-08-31
TW201738277A (zh) 2017-11-01
IL246837B (en) 2020-08-31
TWI695013B (zh) 2020-06-01
CN112390887A (zh) 2021-02-23
TWI697503B (zh) 2020-07-01
RU2016138744A3 (en:Method) 2018-05-11
US20170029526A1 (en) 2017-02-02
EP3129048B1 (en) 2020-01-15
IL276695A (en) 2020-09-30
CN106456727A (zh) 2017-02-22
AU2015243246B2 (en) 2018-09-06
BR112016020009A2 (pt) 2017-10-17
EP3129048A2 (en) 2017-02-15
AU2018253589B2 (en) 2020-04-16
CA2941029A1 (en) 2015-10-15
AU2015243246A1 (en) 2016-09-08
CN112390887B (zh) 2023-09-26
CN106456727B (zh) 2020-11-27
US20180134799A1 (en) 2018-05-17
CA2941029C (en) 2021-02-16
RU2016138744A (ru) 2018-05-11
KR101966408B1 (ko) 2019-04-05
PH12016501976A1 (en) 2016-12-19
ES2772817T3 (es) 2020-07-08
US10815307B2 (en) 2020-10-27
CA3104268A1 (en) 2015-10-15
TW201738276A (zh) 2017-11-01
TWI609886B (zh) 2018-01-01
AU2018253589A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
CL2016002252A1 (es) Anticuerpos anti-egfrviii y usos de los mismos
EP3513809A4 (en) MEDICAL COMPOSITION
BR112016023628A2 (pt) composições farmacêuticas.
DK3297605T3 (da) Topiske, farmaceutiske sammesætninger
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112016026879A2 (pt) Composição farmacêutica líquida
SI4070787T1 (sl) Farmacevtske formulacije
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
DK3199161T3 (da) Farmaceutisk præparat
HUE050779T2 (hu) Folyékony gyógyszerészeti készítmény
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
DK3463345T3 (da) Farmaceutiske kombinationer
LT3191085T (lt) Priklausomybei nuo medikamentų atsparios farmacinės kompozicijos
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
EP3646866A4 (en) PHARMACEUTICAL PREPARATION
DK3280447T3 (da) Farmaceutiske formuleringer
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
HUE069648T2 (hu) Gyógyszerészeti készítmény
CL2017002226A1 (es) Etv2 y usos de los mismos
EP3181125C0 (en) CAPSULE FORMULATION